Loading…
Reported covered position: Legislative Assistant, Senator Byron Dorgan
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Monitor issues related to vision care plans, including H.R.1521 DOC Access Act of 2025. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2025 · first_quarter · 1A
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower. Provide recommendations for the reauthorization of the Pandemic All-Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Highlight how Palantir's technology is being used by hospitals and health systems.
Advocate for funding to support information technology acquisition at the Department of Defense in the FY 26 National Defense Authorization Act. Discuss the importance of funding for the procurement of software for the Department of Defense.
Source: Senate LDA
| URANIUM PRODUCERS OF AMERICA |
| 30 |
| 2014–2021 |
| FITBIT LLC | 28 | 2014–2021 |
| MARATHON OIL | 28 | 2010–2016 |
| AMERICAN BEVERAGE ASSOCIATION | 25 | 2011–2018 |
| PALANTIR TECHNOLOGIES, INC. | 22 | 2020–2025 |
| VSP | 22 | 2017–2025 |
| NEXTERA ENERGY INC | 21 | 2016–2020 |
| POET LLC | 21 | 2017–2021 |
| UNITED STATES STEEL CORPORATION | 19 | 2010–2014 |
| ELI LILLY AND COMPANY | 18 | 2011–2014 |
| AMERICAN AIRLINES | 17 | 2010–2014 |
| ANDURIL INDUSTRIES | 17 | 2017–2021 |
| DSM-FIRMENICH | 17 | 2020–2025 |
| CAPE PRODUCTIONS, INC. | 16 | 2015–2019 |
| MARATHON PETROLEUM | 16 | 2011–2014 |
| MOLEKULE GROUP | 16 | 2019–2022 |
| OXBOW CARBON, LLC | 16 | 2011–2015 |
| ANTHEIA | 15 | 2020–2024 |
| LSB INDUSTRIES | 15 | 2012–2015 |
| MACANDREWS & FORBES GROUP LLC | 13 | 2011–2017 |
| MARRIOTT INTERNATIONAL, INC | 13 | 2014–2017 |
| NAREIT | 13 | 2011–2013 |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS | 13 | 2021–2025 |
| HEALTH CATALYST, INC. | 12 | 2020–2022 |
| HERBALIFE INTERNATIONAL OF AMERICA INC | 12 | 2016–2018 |
| URANIUM ENERGY CORPORATION | 12 | 2011–2014 |
| BIOIQ | 11 | 2020–2023 |
| SOLUGEN, INC. | 11 | 2019–2022 |
| SUNNOVA ENERGY INTERNATIONAL | 11 | 2021–2023 |
| TRINET USA, INC. | 11 | 2020–2023 |
| BABY BAIR FLIGHT VESTS | 10 | 2013–2017 |
| CONCORDE CAREER COLLEGES, INC. | 10 | 2010–2012 |
| GLOBE MANUFACTURING COMPANY, LLC, A SUBSIDIARY OF MSA SAFETY INC. | 10 | 2020–2022 |
| NSS LABS, INC. | 10 | 2013–2015 |
| TRINET GROUP, INC. | 10 | 2017–2019 |
| ACCRETIVE HEALTH | 9 | 2012–2013 |
| Archer Aviation Inc. | 9 | 2021–2023 |
| EMULATE, INC. | 9 | 2018–2020 |
| FUELS AMERICA | 9 | 2015–2016 |
| REGENCY CORPORATION | 9 | 2010–2012 |
| Equian, LLC | 8 | 2018–2019 |
| GROWTH ENERGY | 8 | 2017–2018 |
| MODERN LIFE INC | 8 | 2021–2022 |
| NATIONAL RESTAURANT ASSOCIATION | 8 | 2017–2019 |
| RED BULL NORTH AMERICA, INC | 8 | 2015–2017 |
| SNAP INC. | 8 | 2014–2015 |
| 3M COMPANY | 7 | 2018–2020 |
| ADVANTEK WASTE MANAGEMENT SERVICES LLC | 7 | 2020–2021 |
| HAMPTON CREEK | 7 | 2015–2016 |
| MANAGEMENT SERVICES GROUP, INC., DBA GLOBAL TECHNICAL SYSTEMS | 7 | 2014–2016 |
| SWISS REINSURANCE COMPANY LTD. | 7 | 2014–2018 |
| ACCENTURE FEDERAL SERVICES LLC | 6 | 2021–2022 |
| CARRIER CORPORATION | 6 | 2020–2021 |
| GUARDANT HEALTH, INC. | 6 | 2022–2023 |
| JOBS FOR AMERICA'S GRADUATES | 6 | 2021–2022 |
| READY RESPONDERS | 6 | 2020–2021 |
| AEROSEAL | 5 | 2021–2022 |
| AES PUERTO RICO, L.P. | 5 | 2019–2020 |
| APTALIS PHARMA US, INC. | 5 | 2013 |
| BAYOTECH | 5 | 2021–2022 |
| BERICO TECHNOLOGIES | 5 | 2011 |
| CONCEIVABLE LIFE SCIENCES | 5 | 2024–2025 |
| GOTENNA | 5 | 2018–2020 |
| KERECIS | 5 | 2024–2025 |
| SOCIAL CAPITAL | 5 | 2022–2023 |
| ShiftKey, LLC | 5 | 2024 |
| WAEV INC. | 5 | 2022–2023 |
| WATER AFFORDABILITY COALITION | 5 | 2024–2025 |
| WOUND PROS MANAGEMENT GROUP, INC. | 5 | 2024–2025 |
| ZERRONOX CORPORATION | 5 | 2018 |
| ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) | 4 | 2024–2025 |
| ANCOR | 4 | 2024–2025 |
| BROOKFIELD POWER US ASSET MANAGEMENT | 4 | 2015–2016 |
| CENTER FOR ORGAN RECOVERY & EDUCATION (LOBBYING ON BEHALF OF DONOR ALLIANCE) | 4 | 2021 |
| CITIZEN | 4 | 2020 |
| ECHOSTONE | 4 | 2021 |
| GINGER | 4 | 2019–2020 |
| MILLENNIUM FILMS | 4 | 2015 |
| PALO ALTO NETWORKS | 4 | 2019–2020 |
| RTX CORPORATION | 4 | 2018 |
| SKYRYSE, INC. | 4 | 2022–2023 |
| SOS RHINO | 4 | 2013 |
| SYNAPSE TECHNOLOGIES CORPORATION | 4 | 2018 |
| THE AES CORPORATION | 4 | 2020–2021 |
| CARROT FERTILITY | 3 | 2024–2025 |
| COLLECTIVE HEALTH | 3 | 2016 |
| CSC HOLDINGS LLC | 3 | 2014 |
| EGENESIS INC. | 3 | 2024–2025 |
| EVERLY HEALTH | 3 | 2021 |
| GTX, INC. | 3 | 2018 |
| HEALTHSOUTH CORPORATION | 3 | 2010 |
| PLUM ORGANICS | 3 | 2018 |
| PROJECT VESTA | 3 | 2021–2022 |
| SCHIAVI SEEDS | 3 | 2017 |
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023, and S.5375, Vison Lab Choice Act. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Making Insulin Affordable for All Children Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Drug Price Transparency in Medicaid Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children's mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests. Monitor Emergency Medical Services for Kids Reauthorization.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act and H.R.7808, Early Minds Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health; educate policymakers on Children's Hospitals Graduate Medical Education (CHGME); monitor issues related to lab-developed tests; monitor AI and health care technology privacy; monitor policies related to the 340B program.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests; discuss policies related to children's mental health, including in H.R.7808, EARLY Minds Act; monitor policy related to AI and privacy; discuss policies related to TRICARE.
Helping Kids Cope Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for childrens issues in S.2333, the Pandemic and All Hazards Preparedness Act; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
National Defense Authorization Act for Fiscal Year 2024
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Pharmacy Benefits Manager Accountability Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Recognizing the Role of Direct Support Professionals Act
Client: ANCOR · Firm: INVARIANT LLC
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res 337, H.R. 2941, and S. 1332. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107.
Recognizing the Role of Direct Support Professionals Act
Client: ANCOR · Firm: INVARIANT LLC
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res.337, "National Direct Support Professionals Recognition Week," and H.R. 2941 / S.1332, Recognizing the Role of Direct Support Professionals Act. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107, Ensuring Access to Medicaid Buy-in Programs Act of 2024.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Ensuring Access to Lifesaving Drugs Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Accelerating Kids’ Access to Care Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement, including H.R.4758, Accelerating Kids Access to Care Act.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Lowering Drug Costs for American Families Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Expanding Seniors' Access to Lower Cost Medicines Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes.
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
To amend title 31, United States Code, to reimburse employees of the Federal Government and the District of Columbia, Federal contractors, and the States for certain costs incurred as a result of a Government shutdown, and for other purposes.
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement, including H.R.5758, the Accelerating Kids Access to Care Act.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to price transparency; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act and H.R.7808, Early Minds Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health; educate policymakers on Children's Hospitals Graduate Medical Education (CHGME); monitor issues related to lab-developed tests; monitor AI and health care technology privacy; monitor policies related to the 340B program.
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests; discuss policies related to children's mental health, including in H.R.7808, EARLY Minds Act; monitor policy related to AI and privacy; discuss policies related to TRICARE.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R. 8032/S. 3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res 337, H.R. 2941, and S. 1332. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107.
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res.337, "National Direct Support Professionals Recognition Week," and H.R. 2941 / S.1332, Recognizing the Role of Direct Support Professionals Act. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107, Ensuring Access to Medicaid Buy-in Programs Act of 2024.
Telehealth Benefit Expansion for Workers Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Prescription Pricing for the People Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Pharmacy Benefit Manager Transparency Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res 337, H.R. 2941, and S. 1332. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107.
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res.337, "National Direct Support Professionals Recognition Week," and H.R. 2941 / S.1332, Recognizing the Role of Direct Support Professionals Act. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107, Ensuring Access to Medicaid Buy-in Programs Act of 2024.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023, and S.5375, Vison Lab Choice Act. Educate policymakers on the vision care market.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
National Defense Authorization Act for Fiscal Year 2024
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Pandemic and All-Hazards Preparedness and Response Act
Client: NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS · Firm: INVARIANT LLC
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for childrens issues in S.2333, the Pandemic and All Hazards Preparedness Act; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Modernizing and Ensuring PBM Accountability Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Health Care Prices Revealed and Information to Consumers Explained Transparency Act
Client: CIGNA CORPORATION · Firm: INVARIANT LLC
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to price transparency; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Low-Income Household Water Assistance Program Establishment Act
Client: WATER AFFORDABILITY COALITION · Firm: INVARIANT LLC
Advocate for reauthorization of H.R. 8032/S. 3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023, and S.5375, Vison Lab Choice Act. Educate policymakers on the vision care market.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
A resolution designating the week beginning September 10, 2023, as "National Direct Support Professionals Recognition Week".
Client: ANCOR · Firm: INVARIANT LLC
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res 337, H.R. 2941, and S. 1332. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107.
A resolution designating the week beginning September 10, 2023, as "National Direct Support Professionals Recognition Week".
Client: ANCOR · Firm: INVARIANT LLC
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res.337, "National Direct Support Professionals Recognition Week," and H.R. 2941 / S.1332, Recognizing the Role of Direct Support Professionals Act. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107, Ensuring Access to Medicaid Buy-in Programs Act of 2024.
Disapproving the rule submitted by the Department of Commerce relating to "Procedures Covering Suspension of Liquidation, Duties and Estimated Duties in Accord With Presidential Proclamation 10414".
Client: SUNNOVA ENERGY INTERNATIONAL · Firm: INVARIANT LLC
Educate policymakers on issues related to supply chains and the impact of potential tariffs brought by the preliminary decisions of the Department of Commerce anti-circumvention investigation. Monitor H.J.Res.39, Disapproving the rule submitted by the Department of Commerce relating to "Procedures Covering Suspension of Liquidation, Duties and Estimated Duties in Accord With Presidential Proclamation 10414" and S.J.Res.15, A joint resolution disapproving the rule submitted by the Department of Commerce relating to "Procedures Covering Suspension of Liquidation, Duties and Estimated Duties in Accord With Presidential Proclamation 10414."
Monitor issues related to artificial intelligence.
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUDSON TECHNOLOGIES via INVARIANT LLC
2025 · first_quarter · Q1
Educate Members of Congress and Administration officials about reclaimed refrigerants and advocate for issues related to the implementation of P.L. 116-260, The American Innovation and Manufacturing Act (AIM ACT). Support funding for reclamation under the AIM Act.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
EGENESIS INC. via INVARIANT LLC
2025 · first_quarter · Q1
Educate lawmakers and policymakers on xenotransplantation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONCEIVABLE LIFE SCIENCES via INVARIANT LLC
2025 · first_quarter · Q1
Educate policymakers on technological advancements in the In vitro fertilization health care delivery system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERECIS via INVARIANT LLC
2025 · first_quarter · Q1
Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2025 · first_quarter · Q1
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower. Provide recommendations for the reauthorization of the Pandemic All-Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Highlight how Palantir's technology is being used by hospitals and health systems.
Advocate for funding to support information technology acquisition at the Department of Defense in the FY 26 National Defense Authorization Act. Discuss the importance of funding for the procurement of software for the Department of Defense.
Monitor issues related to artificial intelligence.
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2025 · first_quarter · Q1
Monitor issues affecting the medical device industry, including issues related to the supply chain.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2025 · first_quarter · Q1
Educate lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth.
Monitor issues related to Medicare Part D.
Monitor pharmacy issues related to TRICARE.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CARROT FERTILITY via INVARIANT LLC
2025 · first_quarter · Q1
Educate lawmakers and Administration officials on Carrot Fertility's family building and support platform and services.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) via INVARIANT LLC
2025 · first_quarter · Q1
Discuss issues related to the release of information industry and matters pertaining to patient health information, security, and interoperability.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ANCOR via INVARIANT LLC
2025 · first_quarter · Q1
Encourage support for legislation highlighting the role of direct support professionals in health care. Educate policymakers on issues relating to Medicaid funding and regulations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOUND PROS MANAGEMENT GROUP, INC. via INVARIANT LLC
2025 · first_quarter · Q1
Monitor issues related to wound care management and the importance of food as medicine on wound healing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2025 · first_quarter · Q1
Advocate for reauthorization of the Low-Income Household Water Assistance Program and funding in the FY25 Consolidated Appropriations Act. Advocate for funding in the FY26 Labor, Health and Human Services Appropriations Bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2025 · first_quarter · Q1
Educate policymakers about policies to support children's mental health care needs; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for children's issues in disaster preparedness efforts; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSM-FIRMENICH via INVARIANT LLC
2025 · first_quarter · Q1
Educate policymakers on the importance of UV filters in sunscreen and on issues related to women's health and maternal health.
Discuss regulatory barriers to fragrance commercialization and monitor legislative developments related to new chemical production.
Educate policymakers on the importance of protecting domestic manufacturing capacity of vitamins.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
VSP via INVARIANT LLC
2025 · first_quarter · Q1
Monitor issues related to vision care plans, including H.R.1521 DOC Access Act of 2025. Educate policymakers on the vision care market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2025 · first_quarter · Q1
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; monitor issues related to the VA community care network.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
HEARST CORPORATION via INVARIANT LLC
2025 · first_quarter · Q1
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence-based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Q4
Monitor Homeland Security cybersecurity programs.
Monitor FedRAMP modernization.
Monitor the adoption of cybersecurity tools within the Department of Defense and the defense industrial base.
HEARST CORPORATION via INVARIANT LLC
2024 · fourth_quarter · Q4
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence- based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOUND PROS MANAGEMENT GROUP, INC. via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate policymakers about the use of artificial intelligence on wound care management and the importance of food as medicine on wound healing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · RR
Compliance and cybersecurity
Compliance and cybersecurity
Compliance and cybersecurity
SHIFTKEY, LLC via INVARIANT LLC
2024 · fourth_quarter · Q4
Highlight Shiftkeys technology platform to help health care facilities fill short-term vacancies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KERECIS via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care for servicemembers and veterans.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
HUDSON TECHNOLOGIES via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate Members of Congress and Administration officials about reclaimed refrigerants and advocate for issues related to the implementation of P.L. 116-260, The American Innovation and Manufacturing Act (AIM ACT). Support funding for reclamation under the AIM Act.
Filing targets: Environmental Protection Agency (EPA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, SENATE
CONCEIVABLE LIFE SCIENCES via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate policymakers on technological advancements in the In vitro fertilization health care delivery system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Monitor issues related to Medicare Part D and Medicare Advantage.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2024 · fourth_quarter · Q4
Monitor issues affecting the medical device industry, including issues related to the supply chain and issues; monitor issues related to dialysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTHEIA via INVARIANT LLC
2024 · fourth_quarter · Q4
Encourage support for the domestic manufacturing of active pharmaceutical ingredients.
Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients, support initiatives that expand domestic production capabilities of API, and educate lawmakers on various solutions to enhance drug supply chain resiliency.Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients, support initiatives that expand domestic production capabilities of API, and educate lawmakers on various solutions to enhance drug supply chain resiliency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate Members of Congress about the release of information industry and related policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EGENESIS INC. via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate lawmakers and policymakers on xenotransplantation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · fourth_quarter · Q4
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, CDC Data Modernization Initiative, and ASPR Supply Chain Control Tower. Provide recommendations for the reauthorization of the Pandemic All-Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Highlight how Palantir's technology is being used by hospitals and health systems.
CARROT FERTILITY via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate lawmakers on Carrot Fertility's family building and support platform and services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate policymakers about policies to support children's mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests. Monitor Emergency Medical Services for Kids Reauthorization.
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VSP via INVARIANT LLC
2024 · fourth_quarter · Q4
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023, and S.5375, Vison Lab Choice Act. Educate policymakers on the vision care market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2024 · fourth_quarter · Q4
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2024 · fourth_quarter · Q4
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSM-FIRMENICH via INVARIANT LLC
2024 · fourth_quarter · Q4
Discuss emissions standards for manufacturing. Discuss regulatory barriers to fragrance commercialization and monitor legislative developments related to new chemical production.
Educate policymakers on issues related to women's health and maternal health. Educate policymakers on the importance of domestic manufacturing capacity of vitamins.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ANCOR via INVARIANT LLC
2024 · fourth_quarter · Q4
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res 337, H.R. 2941, and S. 1332. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EGENESIS INC. via INVARIANT LLC
2024 · fourth_quarter · RR
Educate lawmakers on xenotransplantation.
CARROT FERTILITY via INVARIANT LLC
2024 · fourth_quarter · RA
Educate lawmakers on Carrot Fertilitys family building and support platform and services.
ZOCDOC via INVARIANT LLC
2024 · third_quarter · Q3
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOUND PROS MANAGEMENT GROUP, INC. via INVARIANT LLC
2024 · third_quarter · Q3
Educate policymakers about the use of artificial intelligence on wound care management and the importance of food as medicine on wound healing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via INVARIANT LLC
2024 · third_quarter · Q3
Highlight Shiftkeys technology platform to help health care facilities fill short-term vacancies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · third_quarter · Q3
Monitor issues related to artificial intelligence.
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower. Provide recommendations for the reauthorization of the Pandemic All-Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Highlight how Palantir's technology is being used by hospitals and health systems.
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
KERECIS via INVARIANT LLC
2024 · third_quarter · Q3
Educate policymakers about advanced wound care technologies and patient access to skin substitutes for wound care for servicemembers and veterans.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2024 · third_quarter · Q3
Monitor issues affecting the medical device industry, including issues related to the supply chain and issues; monitor issues related to dialysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) via INVARIANT LLC
2024 · third_quarter · Q3
Educate Members of Congress about the release of information industry and related policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2024 · third_quarter · Q3
Advocate for reauthorization of H.R.8032 / S.3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VSP via INVARIANT LLC
2024 · third_quarter · Q3
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HEARST CORPORATION via INVARIANT LLC
2024 · third_quarter · Q3
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence- based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
HUDSON TECHNOLOGIES via INVARIANT LLC
2024 · third_quarter · Q3
Educate Members of Congress and Administration officials about reclaimed refrigerants and advocate for issues related to the implementation of P.L.116-260, The American Innovation and Manufacturing Act (AIM ACT). Support funding for reclamation under the AIM Act in the fiscal year (FY) 2025 Interior and Environment Appropriations Bill.
Discuss the implementation of P.L.116-260, The American Innovation and Manufacturing Act (AIM ACT) and Hudson's support work for the Department of Defense.
Filing targets: Environmental Protection Agency (EPA), Executive Office of the President (EOP), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Small Business Administration (SBA)
DSM-FIRMENICH via INVARIANT LLC
2024 · third_quarter · Q3
Discuss emissions standards for manufacturing.
Educate policymakers on issues related to women's health and maternal health.
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONCEIVABLE LIFE SCIENCES via INVARIANT LLC
2024 · third_quarter · Q3
Educate policymakers on technological advancements in the In vitro fertilization health care delivery system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COOK INLET REGION INCORPORATED (CIRI) via INVARIANT LLC
2024 · third_quarter · Q3
Monitored provisions related to tribal consultation in the Alaska Native Claims Settlement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · third_quarter · Q3
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Monitor issues related to Medicare Part D and Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2024 · third_quarter · Q3
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act and H.R.7808, Early Minds Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health; educate policymakers on Children's Hospitals Graduate Medical Education (CHGME); monitor issues related to lab-developed tests; monitor AI and health care technology privacy; monitor policies related to the 340B program.
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement, including H.R.4758, Accelerating Kids Access to Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTHEIA via INVARIANT LLC
2024 · third_quarter · Q3
Encourage support for the domestic manufacturing of active pharmaceutical ingredients.
Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients, support initiatives that expand domestic production capabilities of API, and educate lawmakers on various solutions to enhance drug supply chain resiliency.
Filing targets: Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, SENATE
ANCOR via INVARIANT LLC
2024 · third_quarter · Q3
Encourage support for legislation highlighting the role of direct support professionals in health care, including S.Res.337, "National Direct Support Professionals Recognition Week," and H.R. 2941 / S.1332, Recognizing the Role of Direct Support Professionals Act. Educate policymakers on issues relating to Medicaid funding and regulations, including H.R. 8107, Ensuring Access to Medicaid Buy-in Programs Act of 2024.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANCOR via INVARIANT LLC
2024 · third_quarter · RR
Highlight the role of direct support professionals, Medicaid
ALLIANCE FOR HEALTH INFORMATION OPERATIONS AND STANDARDS (AHIOS) via INVARIANT LLC
2024 · third_quarter · RR
Highlight the role of direct support professionals, Medicaid
COOK INLET REGION INCORPORATED (CIRI) via INVARIANT LLC
2024 · third_quarter · RR
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
KERECIS via INVARIANT LLC
2024 · second_quarter · Q2
Educate policymakers about patient access to skin substitutes for wound care for servicemembers and veterans in fiscal year 2025 National Defense Authorization Act (NDAA) and fiscal year 2025 Consolidated Appropriations Act.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · second_quarter · Q2
Educate lawmakers on pharmacy issues related to TRICARE and H.R. 8070, the Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year.
Monitor issues related to Medicare Part D and Medicare Advantage.
Educare lawmakers on issues related to pharmacy benefit managers and drug pricing; proposals impacting employer-sponsored insurance; proposals related to telehealth; issues related to privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WOUND PROS MANAGEMENT GROUP, INC. via INVARIANT LLC
2024 · second_quarter · Q2
Monitor issues related to wound care management.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via INVARIANT LLC
2024 · second_quarter · Q2
Highlight Shiftkeys technology platform to help health care facilities fill short-term vacancies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2024 · second_quarter · Q2
Monitor issues affecting the medical device industry, including issues related to the supply chain and issues; monitor issues related to dialysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ZOCDOC via INVARIANT LLC
2024 · second_quarter · Q2
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WATER AFFORDABILITY COALITION via INVARIANT LLC
2024 · second_quarter · Q2
Advocate for reauthorization of H.R. 8032/S. 3830 the Low-Income Household Water Assistance Program Establishment Act and funding in the FY25 Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VSP via INVARIANT LLC
2024 · second_quarter · Q2
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · second_quarter · Q2
Monitor issues related to artificial intelligence.
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
Discuss how commercial technology can improve border security.
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2024 · second_quarter · Q2
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement, including H.R.5758, the Accelerating Kids Access to Care Act.
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests; discuss policies related to children's mental health, including in H.R.7808, EARLY Minds Act; monitor policy related to AI and privacy; discuss policies related to TRICARE.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HUDSON TECHNOLOGIES via INVARIANT LLC
2024 · second_quarter · Q2
Educate Members of Congress and Administration officials about reclaimed refrigerants and advocate for issues related to the implementation of P.L.116-260, The American Innovation and Manufacturing Act (AIM ACT). Support funding for reclamation under the AIM Act in the fiscal year (FY) 2025 Interior and Environment Appropriations Bill.
Filing targets: Defense, Dept of (DOD), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA)
HEARST CORPORATION via INVARIANT LLC
2024 · second_quarter · Q2
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence- based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSM-FIRMENICH via INVARIANT LLC
2024 · second_quarter · Q2
Educate policymakers on the importance of UV filters in sunscreen, the importance of domestic manufacturing capacity of vitamins, issues related to women's health, and other DSM products.
Discuss emissions standards for manufacturing and net metering for solar fields.
Filing targets: Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ANTHEIA via INVARIANT LLC
2024 · second_quarter · Q2
Encourage support for the domestic manufacturing of active pharmaceutical ingredients.
Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients, support initiatives that expand domestic production capabilities of API, and educate lawmakers on various solutions to enhance drug supply chain resiliency.
Filing targets: Executive Office of the President (EOP), Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, SENATE
CONCEIVABLE LIFE SCIENCES via INVARIANT LLC
2024 · third_quarter · RA
Educate policymakers on issues related to fertility and IVF
CONCEIVABLE LIFE SCIENCES via INVARIANT LLC
2024 · second_quarter · RR
Educate policymakers on issues related to fertility and IVF
WOUND PROS MANAGEMENT GROUP, INC. via INVARIANT LLC
2024 · second_quarter · RR
Innovative wound care management
WATER AFFORDABILITY COALITION via INVARIANT LLC
2024 · second_quarter · RR
Low Income Household Water Assistance Program (LIHWAP)
KERECIS via INVARIANT LLC
2024 · first_quarter · Q1
Educate policymakers on the benefits of skin substitutes for wound care for servicemembers and veterans in fiscal year 2025 National Defense Authorization Act and fiscal year 2025 Consolidated Appropriations Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DSM-FIRMENICH via INVARIANT LLC
2024 · first_quarter · Q1
Discuss emissions standards for manufacturing and net metering for solar fields.
Educate policymakers on the importance of UV filters in sunscreen, the importance of domestic manufacturing capacity of vitamins, issues related to women's health, and other DSM products.
Filing targets: Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ZOCDOC via INVARIANT LLC
2024 · first_quarter · Q1
Educate Members of Congress about the potential to use technology to improve access to care, reduce wait time, and improve patient engagement; discuss issues related to price transparency; discuss issues related to the Anti-Kickback Statute; discuss issues related to ghost networks; discuss issues related to the health care workforce; encourage support for H.R.7292 / S.3744, the Health ACCESS Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VSP via INVARIANT LLC
2024 · first_quarter · Q1
Monitor issues related to vision care plans, including S.1424 / H.R.1385 DOC Access Act of 2023. Educate policymakers on the vision care market.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via INVARIANT LLC
2024 · first_quarter · Q1
Discussed how the company leverages technology to fill health care workforce vacancies.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · first_quarter · Q1
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform. Provide recommendations for the reauthorization of the Pandemic All- Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Support funding for ASPR Supply Chain Control Tower.
Monitor issues related to artificial intelligence.
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
PALANTIR TECHNOLOGIES INC. via INVARIANT LLC
2024 · first_quarter · Q1
Discuss how commercial technology can be leveraged by IRS to fight fraud and improve customer experience.
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform. Provide recommendations for the reauthorization of the Pandemic All- Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Support funding for ASPR Supply Chain Control Tower.
Monitor issues related to artificial intelligence.
HEARST CORPORATION via INVARIANT LLC
2024 · first_quarter · Q1
Monitor implementation of Medicare appropriate use criteria; educate Members of Congress about the importance of independent, evidence- based care guidelines; monitor mental health legislation, including mental health parity. Monitor issues related to prior authorization. Monitor issues related to home health reimbursement. Monitor issues related to the use of artificial intelligence in health care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2024 · first_quarter · Q1
Educate policymakers on issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R.2880, ProtectingPatients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title Ill of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients' Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S.2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 4508, Hidden Fee Disclo sure Act; H.R.3285, Fairness for Patient Medications Act; S.2973 Modemizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0). Educate policymakers on H.R.3285 - Faimess for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 6986/S.3583, to address patent thickets.
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2024 · first_quarter · Q1
Monitor policies to improve children's Medicaid and issues related to Medicaid reimbursement.
Educate policymakers about policies to support children mental health care needs, including H.R.2412, the Helping Kids Cope Act; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for childrens issues in S.2333, the Pandemic and All Hazards Preparedness Act; discuss the impact of pediatric workforce and drug/supply shortages and its impact on child health. Monitor issues related to lab-developed tests.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via INVARIANT LLC
2024 · first_quarter · Q1
Monitor issues affecting the medical device industry, including issues related to the supply chain and issues; monitor issues related to dialysis.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIFTKEY, LLC via INVARIANT LLC
2024 · first_quarter · RR
Health care workforce
ARCHER AVIATION INC. via INVARIANT LLC
2023 · second_quarter · Q2
Advocate for funding programs related to eVTOL aircraft and infrastructure in the FY24 Transportation, Housing and Urban Development, and related agencies appropriations bill.
Educate policymakers about Archer and eVTOL aircraft technology. Monitor and advocate for provisions in the House and Senate FAA reauthorization process (H.R.3935 and S.1939).
Educate policymakers on importance of small businesses and American innovation.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
CIGNA CORPORATION via INVARIANT LLC
2023 · second_quarter · Q2
Issues related to S. 113, the Prescription Pricing for the People Act, and S. 127, the Pharmacy Benefit Manager Transparency Act and issues related to insulin pricing.
Pharmacy issues related to TRICARE and the Fiscal Year 2024 National Defense Authorization Act.
Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOCIAL CAPITAL via INVARIANT LLC
2023 · second_quarter · 2T
Introduce social capital and highlight the efforts of Akili to develop prescription digital therapies.
Filing targets: SENATE
2023 · second_quarter · 2T
Advocate for reforms in USAID contracting to promote transparency and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Q2
Support efforts to extend commercial and clean vehicle tax credits to LSVs in the implementation of P.L. 117-169, Inflation Reduction Act.
Support the study and consideration of low-speed vehicle utilization at Department of Defense facilities.
Discuss the benefits of electric low speeds vehicles (LSVs). Support General Services Administration (GSA) and National Park Service efforts to reduce greenhouse gas emissions using low-speed vehicles in the Financial Services and General Government and Interior Appropriations bills.
Filing targets: Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA)
FEDERATION OF AMERICAN HOSPITALS via INVARIANT LLC
2023 · second_quarter · Q2
Monitor federal health care policy, including Medicare and Medicaid payment for hospital care. Monitor extension of payments to rural hospitals. Monitor provisions that would weaken or repeal current law limiting self-referral to physician-owned hospitals. Advocate on issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS via INVARIANT LLC
2023 · second_quarter · Q2
Monitor policies to improve childrens Medicaid and issues related to Medicaid reimbursement.
Educate policymakers about policies to support childrens mental health care needs; support funding for CHGME; monitor House and Senate work on pediatric and adolescent mental health. Advocate for childrens issues in the Pandemic and All Hazards Preparedness Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUNNOVA ENERGY INTERNATIONAL via INVARIANT LLC
2023 · second_quarter · Q2
Educate policymakers about Sunnova; discuss issues related to solar, including net metering, microgrids, and policies to make solar accessible and affordable to all households. Discuss rooftop solar programs in Puerto Rico and efforts to help rebuild rooftop solar in Guam. Encourage the DOE to study the rate of residential rooftop solar installations and improve interconnection processes in the Energy and Water Appropriations bill for fiscal year (FY) 2024.
Support and monitor implementation of P.L. 117-169, Inflation Reduction Act. Monitor H.R. 3938, the Build it in America Act.
Discuss how commercial technology can improve border security.
Monitor issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
Educate policymakers on CIRI, its businesses, and priorities regarding Alaska Native issues.
Support funding for the National Institutes of Health N3C Program and Centers for Disease Control and Prevention Ready Response Data Integration Platform, and ASPR Supply Chain Control Tower. Provide recommendations for the reauthorization of the Pandemic All-Hazards Preparedness Act and related legislation, highlighting ongoing work at ASPR. Discuss improvements to the organ transplant network IT and software infrastructure. Highlight how Palantir's technology is being used by hospitals and health systems.
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocate for funding to support information technology acquisition at the Department of Defense. Discuss the importance of funding for the procurement of software.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers on S. 1967, the Patients Before Middlemen (PBM) Act, establishing new requirements relating to the responsibility of pharmacy benefit managers under Medicare part D; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 5376, the Share the Savings with Seniors Act; H.R. 5385, the Medicare PBM Accountability Act; H.R. 5393, the Transparency and Fairness for Pharmacies Act; H.R. 5372, the Expanding Seniors' Access to Lower Cost Medicines Act of 2023; S. 3430, the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act (the Better Act); Issues related to Pharmacy Direct and Indirect Remuneration (DIR), including the Contract Year (CY) 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit (Part D) Programs proposed rule.
Educate policymakers on pharmacy issues related to TRICARE and H.R. 2670, S.2226 Fiscal Year 2024 National Defense Authorization Act.
Educate policymakers on health care issues related to P.L. 118-42, the Consolidated Appropriations Act 2024, and P.L. 118-47, the Further Consolidated Appropriations Act; Issues related to P.L. , the Inflation reduction Act of 2022, including enhanced advance premium tax creidts (APTCs) and Medicare Part D redisign; S. 727, Inslulin for All Act of 2023; S.1269, Improving Needed Safeguards for Uses of Lifesaving Insulin Now (INSULIN) Act of 2023; S. 146 Cap Insulin Prices Act; S. 954 Affordable Insulin Now Act of 2023; H.R. 1488, Affordable Insulin Now Act; H.R. 1587, Making Insulin Affordable for All Children Act; HR 1485, Insulin for All Act of 2023; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 1843 / S.1001, Telehealth Expansion Act; H.R. 824, Telehealth Benefit Expnsion for Workers Act of 2023; Issues related to artificial intelligence and health care issues; Issues related to the proposed rule on Advancing Interoperability and Improving Prior Authorization Processes for Mediare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-facilitated Exchanges, Merit-based Incentive Payment System (MIPS) Eligibile Clinicians, and Eligible Hospitals and Critical Access Hospitals in the Medicare Promoting Interoperability Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Educate policymakers on issues related to supply chains and the impact of potential tariffs brought by the preliminary decisions of the Department of Commerce anti-circumvention investigation. Monitor H.J.Res.39, Disapproving the rule submitted by the Department of Commerce relating to "Procedures Covering Suspension of Liquidation, Duties and Estimated Duties in Accord With Presidential Proclamation 10414" and S.J.Res.15, A joint resolution disapproving the rule submitted by the Department of Commerce relating to "Procedures Covering Suspension of Liquidation, Duties and Estimated Duties in Accord With Presidential Proclamation 10414."
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), Maritime Administration (MARAD), SENATE